AtezoTRIBE Trial: Atezolizumab Plus FOLFOXIRI Improves PFS in Metastatic Colorectal Cancer

Scientific Contributions by Alboukadel Kassambara

The AtezoTRIBE phase 2 trial demonstrates that adding atezolizumab to FOLFOXIRI-bevacizumab improves progression-free survival in metastatic colorectal cancer patients. Biomarker-based survival modeling explored predictive value of immune signatures such as Immunoscore-IC.

Scientific Abstracts
Author
Affiliation
Published

May 27, 2022

Modified

May 21, 2025

Keywords

Alboukadel Kassambara, AtezoTRIBE, colorectal cancer, immunotherapy, FOLFOXIRI, atezolizumab, Immunoscore-IC, biomarker analysis, survival modeling

Antoniotti C, Rossini D, Pietrantonio F, Catteau A, Salvatore L, Lonardi S, Boquet I, Tamberi S, Marmorino F, Moretto R, Ambrosini M, Tamburini E, Tortora G, Passardi A, Bergamo F, Kassambara A, Sbarrato T, Morano F, Ritorto G, Borelli B, Boccaccino A, Conca V, Giordano M, Ugolini C, Fieschi J, Papadopulos A, Massoué C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Fontanini G, Boni L, Galon J, Cremolini C. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet Oncology. 2022. Download the PDF

Summary of the Study

This phase 2 trial evaluated whether adding atezolizumab, an anti–PD-L1 immune checkpoint inhibitor, to FOLFOXIRI plus bevacizumab improves outcomes in patients with previously untreated metastatic colorectal cancer (mCRC).

  • 218 patients were randomized (1:2) to receive:

    • FOLFOXIRI + bevacizumab (control)
    • FOLFOXIRI + bevacizumab + atezolizumab (experimental)
  • Median follow-up: 19.9 months

Key Results

  • Median progression-free survival (PFS):

    • 13.1 months in the atezolizumab group vs 11.5 months in control
    • HR = 0.70, p = 0.018
  • Safety profile was manageable, with expected grade 3–4 toxicities (e.g., neutropenia, diarrhea)

  • Two treatment-related deaths occurred in the atezolizumab arm

Biomarker Insight

In-depth exploratory analysis included immunological biomarkers such as Immunoscore-IC to assess predictive value for response stratification.

Important

In this study, Alboukadel Kassambara contributed to the statistical analysis and survival modeling, specifically evaluating the predictive value of immune biomarkers such as Immunoscore-IC in the context of clinical response to atezolizumab.

Citation

Publication: In The Lancet Oncology
Date: May 27, 2022
Type: Journal Article
PDF: Download the PDF

< Back to all abstracts

Scientific Contributions

Note

Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.

placeholder

placeholder
No matching items
Back to top